Vertex starts Phase II study of VX-745 in RA

VRTX began U.S. placebo-controlled Phase II testing of its VX-745 inhibitor of p38 mitogen activated protein kinase (MAPK) in 135 patients with rheumatoid arthritis (RA) not responding to their existi...